AUTHORS
Ricardo Daniel Parrondo, MD, Athanasios Tsalatsanis, PhD2, Julio C Chavez, MD, MS3, Sikander Ailawadhi, MD4, Hong Qin, MD, PhD5, Ambuj Kumar, MD, MPH6, Mohamed Kharfan-Dabaja, MD7
AFFILIATIONS
1 Mayo Clinic, Jacksonville, Florida, United States
2 University of South Florida, Tampa, Florida, United States
3 Mayo Clinic, Jacksonville, Florida, United States
4 Mayo Clinic, Jacksonville, Florida, United States
5 Mayo Clinic, Jacksonville, Florida, United States
6 University of South Florida, Tampa, Florida, United States
7 Mayo Clinic, Jacksonville, Florida, United States
ABSTRACT
Background: There have not been any prospective clinical trials comparing the two FDA approved anti-BCMA CAR-T cell therapies for the treatment of relapsed/refractory multiple myeloma (RRMM), namely ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel). As the clinical trials evaluating these therapies in late-line (CARTITUDE-1 for cilta-cel and KARMMA-1 for ide-cel) and early-line (CARTITUDE-4 for cilta-cel and KARMMA-3 for ide-cel) RRMM had different patient populations in terms of prior lines of therapy and drug-refractoriness, it is difficult to compare the safety and efficacy of these two CAR-T products. A comparative analysis of real-world multi-institutional data from a total of 641 patients (pts) with RRMM after ≥4 prior lines of therapy revealed that cilta-cel is associated with a higher likelihood of ≥grade 3 cytokine release syndrome (CRS) as well as higher likelihood of ≥complete response, and longer progression-free survival (PFS) and overall survival (OS) compared to ide-cel (n=386). However, this study only had 13 months of follow-up, included only 641 pts who received cilta-cel or ide-cel after ≥4 prior lines of therapy, and did not capture differences in healthcare utilization such as readmission rates. To evaluate the real-world difference between cilta-cel and ide-cel with a larger patient cohort with longer follow-up, we performed a retrospective cohort study using a large, multi-institutional electronic health record database.
Methods: We conducted a multicenter retrospective cohort study using the TriNetX Global Health Research Network to identify pts with (RRMM) who received either cilta-cel or ide-cel therapy from March 1, 2021, through July 1, 2026. The index event was the start of the relevant study therapy. The TriNetX propensity-score matching adjusted for age at index event and gender. Follow-up for the original survival analyses was limited to 5 years. Key outcomes included overall survival (OS) rates at 1,2, and 5-years post-CAR-T, any grade cytokine release syndrome (CRS), any grade immune effector cell neurotoxicity syndrome (ICANS), and readmission rates. Kaplan-Meier analysis was used to estimate OS. CRS and ICANS were graded using the established ASTCT criteria.
Results: Among 1455 pts identified, 603 received ide-cel and 852 received cilta-cel. After performing 1:1 propensity score matching, 591 pts received ide-cel and 591 received cilta-cel for a total of 1182 pts in the final matched cohort. Both the cilta-cel and ide-cel groups were balanced for age, gender, and race with a median age at index of 65.9 years for both groups, 57.9% and 57.7% male sex for cilta-cel and ide-cel, respectively and 67.3% vs. 71.5% white race in the cilta-cel and ide-cel groups respectively (p=0.115). The 1-year OS was superior for cilta-cel (90.4% vs. 84.5%, p=0.011). This was also the case for the 3-year OS (75.3% vs. 67.8%, p=0.011), and the 5-year OS (75.3% vs. 55.9%, p=0.008). There were no differences in any grade CRS between cilta-cel (45.3%) and ide-cel (47.4%), p=0.559, and there were no differences in any grade immune effector cell associated neurotoxicity syndrome (ICANS) between cilta-cel (19.9%) and ide-cel (19.8%), p=0.941. There was a higher 30-day readmission rates with cilta-cel (55.0%) vs. ide-cel (41.6%), p<0.0001.
Conclusions: In this large propensity score-matched real-world cohort, cilta-cel demonstrated superior OS at 1-year, 3-year and 5-year compared with ide-cel without an increase in the incidence of any-grade CRS or ICANS. Cilta-cel was associated with higher 30-day readmission rates. These findings extend prior real-world comparisons by including a larger patient population, longer follow-up, and assessment of healthcare utilization, providing additional evidence supporting the comparative effectiveness of cilta-cel in patients with RRMM.
DISCLOSURES
Ricardo Daniel Parrondo, MD: Sanofi Aventis - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony)